The initial drug therapy for acute coronary syndrome (ACS) centers on a combination of antiplatelet agents, anticoagulants, anti-ischemic medications, and a high-intensity statin, all started as quickly as possible after presentation. The exact combination depends on whether the patient has a STEMI, NSTEMI, or unstable angina, and whether the treatment plan involves catheterization or a more conservative approach.
Aspirin: The First Priority
Aspirin is given immediately to every ACS patient who doesn’t have an absolute contraindication. The loading dose is 162 to 325 mg, and the tablet should be chewed (non-enteric coated) rather than swallowed whole to speed up its antiplatelet effect. This applies regardless of whether the patient will eventually undergo catheterization or be managed with medications alone. For patients who can’t take anything by mouth, rectal or intravenous routes are alternatives. After the loading dose, a lower daily maintenance dose continues indefinitely.
Adding a Second Antiplatelet Agent
Alongside aspirin, a second antiplatelet drug from the P2Y12 inhibitor class is started to form what’s known as dual antiplatelet therapy. Three options exist: clopidogrel, ticagrelor, and prasugrel. The choice depends heavily on the clinical scenario.
STEMI Patients
For STEMI patients receiving clot-dissolving therapy (fibrinolysis), clopidogrel is the recommended P2Y12 inhibitor at a 300 mg loading dose, followed by 75 mg daily. Patients older than 75 skip the loading dose and go straight to 75 mg. Ticagrelor and prasugrel haven’t been adequately studied alongside fibrinolysis and carry a higher bleeding risk in that setting.
For STEMI patients going directly to catheterization for primary PCI, all three agents are options. Ticagrelor is loaded at 180 mg (then 90 mg twice daily), prasugrel at 60 mg (then 10 mg daily), and clopidogrel at 600 mg (then 75 mg daily). Ticagrelor and prasugrel are generally preferred over clopidogrel here because of their stronger and more consistent antiplatelet effect.
NSTEMI and Unstable Angina
The principal difference in managing NSTEMI and unstable angina, compared to STEMI, is that the initial focus is on medical therapy while clinicians decide on the timing and appropriateness of catheterization. For patients heading toward an early invasive strategy, ticagrelor or prasugrel are the first-choice P2Y12 inhibitors. Clopidogrel is an alternative when those aren’t suitable. For patients being managed conservatively with an ischemia-guided approach, ticagrelor is preferred. Prasugrel should be avoided in this group because it raises bleeding risk without clear benefit in patients not undergoing PCI.
Anticoagulation
Every ACS patient also receives an anticoagulant alongside the antiplatelet agents. Unfractionated heparin is the most common choice, given intravenously with weight-based dosing. Guidelines recommend an initial bolus of 60 to 70 units per kilogram (capped at 5,000 units), followed by a continuous infusion of 12 to 15 units per kilogram per hour (capped at 1,000 units per hour). For patients going to PCI without additional platelet-blocking agents, higher bolus doses of 70 to 100 units per kilogram are used.
Enoxaparin, a low-molecular-weight heparin, is an alternative. It’s given as a subcutaneous injection at 1 mg per kilogram twice daily and is one of the most frequently used anticoagulants in NSTEMI. If a patient on enoxaparin goes to the catheterization lab and the last dose was more than 8 hours ago, an additional intravenous bolus of 0.3 mg per kilogram is given at that time.
Anti-Ischemic Therapy
Nitroglycerin is used to relieve ongoing chest pain and reduce the heart’s workload. It’s typically given sublingually first and then as a continuous intravenous infusion if pain persists. One critical safety point: nitroglycerin must not be given to anyone who has recently used a PDE5 inhibitor for erectile dysfunction. The American Heart Association specifies a minimum wait of 24 hours after fast-acting agents and 48 hours after longer-acting ones before nitrates can be safely administered.
Beta blockers are started orally within the first 24 hours for both STEMI and NSTEMI patients, as long as they don’t have signs of heart failure, a low-output state, elevated risk for cardiogenic shock, or specific conduction problems like second- or third-degree heart block or a prolonged PR interval. Active asthma and reactive airways disease are also contraindications. When it’s safe to use them, beta blockers lower heart rate and reduce the heart’s oxygen demand, helping to limit further damage.
Oxygen Therapy
Supplemental oxygen is not given to every ACS patient. Current guidelines recommend it only when oxygen saturation drops below 90 to 94%, with the flow rate adjusted to keep levels in that range. Routine high-flow oxygen in patients with normal saturation levels has not been shown to improve outcomes and may even be harmful, based on trial data comparing liberal oxygen use to a more selective approach.
High-Intensity Statin Therapy
A high-intensity statin is started during the initial hospitalization, not saved for an outpatient follow-up. High-intensity statin therapy means atorvastatin at 40 to 80 mg or rosuvastatin at 20 to 40 mg daily. Starting early stabilizes arterial plaques and reduces the risk of further cardiovascular events. This medication continues long-term after discharge.
A Note on Pain Management
Morphine has traditionally been used for severe chest pain that doesn’t respond to nitroglycerin. However, it has come under increasing scrutiny because multiple trials have shown that morphine delays and weakens the absorption of P2Y12 inhibitors, potentially blunting their antiplatelet effect at exactly the moment it matters most. This interaction doesn’t mean morphine is never used, but clinicians now weigh this trade-off more carefully and may reserve it for patients with refractory pain.